Engineered anti-IL-23R antibodies
View Patent ↗Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders.
1. A binding compound that binds to human IL-23R comprising:
a) an antibody light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein:
CDRL1 comprises the sequence of SEQ ID NO: 27;
CDRL2 comprises the sequence of SEQ ID NO: 32; and
CDRL3 comprises the sequence of SEQ ID NO: 37; and
b) an antibody heavy chain variable domain, or antigen binding fragment thereof, comprising CDRH1, CDRH2 and CDRH3, wherein:
CDRH1 comprises the sequence of SEQ ID NO: 12;
CDRH2 comprises the sequence of SEQ ID NO: 17; and
CDRH3 comprises the sequence of SEQ ID NO: 22.
2. The binding compound of claim 1 , further comprising:
a) human germline light chain framework sequences in the antibody light chain variable domain; and
b) human germline heavy chain framework sequences in the antibody heavy chain variable domain.
3. The binding compound of claim 1 , further comprising a γ1 human heavy chain constant region or a variant thereof covalently linked to the antibody heavy chain variable domain, wherein the constant region variant comprises up to 20 conservative amino acid substitutions.
4. The binding compound of claim 1 , further comprising a γ4 human heavy chain constant region or a variant thereof covalently linked to the antibody heavy chain variable domain, wherein the constant region variant comprises up to 20 conservative amino acid substitutions.
5. The binding compound of claim 1 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
6. A pharmaceutical composition comprising the binding compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.
7. A binding compound that binds to human IL-23R, comprising:
a) an antibody light chain variable domain comprising the sequence of SEQ ID NO: 58; and
b) an antibody heavy chain variable domain comprising the sequence of SEQ ID NO: 57.
8. A binding compound that binds to human IL-23R, comprising:
a) an antibody light chain variable domain consisting essentially of the sequence of SEQ ID NO: 58; and
b) an antibody heavy chain variable domain consisting essentially of the sequence of SEQ ID NO: 57.
9. An antibody, or antigen binding fragment thereof, that binds to the same epitope as a binding compound comprising:
a) an antibody light chain comprising the variable domain sequence of SEQ ID NO: 58; and
b) an antibody heavy chain comprising the variable domain sequence of SEQ ID NO: 57.
10. An antibody, or antigen binding fragment thereof, that binds to the same epitope of human IL-23R as the antibody produced by the hybridoma deposited with ATCC under accession number PTA-7800.